Phase II trial of didox in advanced breast cancer
1991
Trial of Didox in Advanced Breast Cancer
Sample size: 14
publication
Evidence: low
Author Information
Author(s): R.D. Rubens, S.B. Kaye, M. Soukop, C.J. Williams, M.H. Brampton, A.L. Harris
Primary Institution: Guy's Hospital, London
Hypothesis
Can didox be effective in treating advanced breast cancer?
Conclusion
Didox showed no effectiveness in treating advanced breast cancer in the patients studied.
Supporting Evidence
- None of the 14 patients responded to didox treatment.
- Twelve patients died with a median survival of 3.5 months.
- Toxicity from didox was minimal, with mild nausea and alopecia reported.
Takeaway
The study tested a drug called didox on patients with advanced breast cancer, but it didn't help anyone.
Methodology
Patients with advanced breast cancer were treated with didox administered intravenously every 3 weeks.
Limitations
The study had a small sample size and included patients who had already undergone multiple treatments.
Participant Demographics
Median age of participants was 58 years, with a range of 40-69 years.
Want to read the original?
Access the complete publication on the publisher's website